NCT05511519 - Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

December 6, 2023

Study Completion Date

January 3, 2024

Conditions

Psoriatic Arthritis

Interventions

DRUG

ATI-450

Oral, small molecule MK2 inhibitor

DRUG

Placebo Oral Tablet

Placebo tablet manufactured to match ATI-450 in appearance

Trial Locations (22)

16635

Aclaris Investigational Site, Duncansville

28210

Aclaris Clinical Operations, Charlotte

33014

Aclaris Investigational Site, Miami Lakes

33613

Aclaris Investigational Site, Tampa

38119

Aclaris Investigational Site, Memphis

43551

Aclaris Investigational Site, Perrysburg

75150

Aclaris Investigational Site, Mesquite

07728

Aclaris Clinical Operations, Freehold

15-707

Aclaris Investigational Site, Bialystok

85-168

Aclaris Investigational Site, Bydgoszcz

42-200

Aclaris Investigational Site, Częstochowa

40-040

Aclaris Investigational Site, Katowice

40-081

Aclaris Investigational Site, Katowice

30-363

Aclaris Investigational Site, Krakow

30-510

Aclaris Investigational Site, Krakow

10-341

Aclaris Investigational Site, Olsztyn

60-702

Aclaris Investigational Site, Poznan

37-450

Aclaris Investigational Site, Stalowa Wola

70-332

Aclaris Investigational Site, Szczecin

87-100

Aclaris Investigational Site, Torun

04-141

Aclaris Investigational Site, Warsaw

50-381

Aclaris Investigational Site, Wroclaw